ASAP Innovations will feature its X-TRA Thick Black glove at the world’s biggest Health and Safety Event
ASAP Innovations, a leading global PPE manufacturer, has today announced that its X-TRA Thick Black glove has been approved for use throughout the EU and in the UK; the glove offers the highest protection against exposure to many commonly – used chemotherapy drugs.
The X-TRA Thick Black glove has been tested in accordance with ISO 16604:2004 (resistance to penetration by blood – borne pathogens) and has passed to meet the requirements of EN ISO 374-5:2016.
The gloves have been approved for use with a wide range of commonly used chemotherapy drugs, including Cisplatin and Cyclophosphamide (Cytoxan). In addition, they have full – hand texture for enhanced grip, and are powder – free.
ASAP Innovations was founded in 2018 and is part of ASAP International, a group that started in Malaysia in 1988; the company now has a presence in over 80 countries worldwide, with an extensive range of products used in multiple sectors, including aerospace, automotive, cleanroom, healthcare, food and drink, hospitality, industrial and more.
A + A will take place at the Messe Dusseldorf from 26th – 29th October; it is the world’s biggest exhibition dedicated to Health and Safety. ASAP International is on Stand E87, Hall 3.
ASAP Innovation’s gloves are available from the company’s European Distribution Partners.
Sean Keller, Managing Director at ASAP Innovations, commented; “We are particularly delighted to have achieved this approval for the European market, as it means our gloves can be used with complete confidence in the highly challenging environments where chemotherapy drugs are dispensed and delivered.”